

To,

Date: 14.09.2020

BSE Limited P.J. Towers, Dalal Street, Mumbai - 400 001	Metropolitan Stock Exchange of India Limited Vibgyor Towers, 4 th floor, Plot No. C62, Opp. Trident Hotel, Bandra Kurla Complex, Bandra (E), Mumbai- 400 098
---	--

Dear Sir/Madam,

Sub: Outcome of board meeting under Regulation 30 read with 33 (3) (c) of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015

Ref: (Scrip code: 539267/ DRHABEEB)

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Dr Habeebullah Life Sciences Limited held on Monday, 14.09.2020 at 3.30 P.M. at the registered office of the Company, the following were considered and approved by the Board:

1. Un-Audited financial results (Standalone & Consolidated) for the quarter ended 30.06.2020.
2. Limited Review Report (standalone & consolidated) along with Declaration as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for the quarter ended 30.06.2020


The meeting of the Board of Directors commenced at 03:30 P.M. (IST) and concluded at 5 P.M (IST).

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,

For Dr Habeebullah Life Sciences Limited


K. Krishnam Raju

Whole-Time Director

(DIN: 00874650)



Encl: as above

Dr Habeebullah Life Sciences Ltd


(Formerly Known as PC Products India Limited)

Regd. Off : 2-5-36/CLRD/1, Chintalmet X Roads, Upperpally, Rajendra Nagar Mandal, Hyderabad-500048. TS. India.
Corp Off : No.11, Phase I, Vasudeva's Bloomfield Elation, Khajaguda, Nanakramguda, Hyderabad-500008. TS. India.
CIN No.: L85110TG1996PLC099198. Email: cs@drhsl.com, info@drhsl.com, pcproductsindia@gmail.com
Contact No.: 040 - 2970 3333, +91 9030057370. Website: www.drhsl.com

PART-I

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER I ENDED 30TH JUNE, 2020

S.No	Particulars	Quarter ended			Previous Year Ended 31-03-2020
		3 Months ended 30-06-2020	Preceding 3 months ended 31-03-2020	Corresponding 3 months ended in previous year 30-06-2019	
		Unaudited	Audited	Unaudited	
I	Revenue from Operations	1.30	24.20	42.22	143.19
II	Other Income	3.54	5.20	-	15.82
III	Total Revenue (I+II)	4.84	29.40	42.22	159.01
IV	Expenses				
	Cost of Material Consumed	0.19	3.03	7.25	22.49
	Employee benefits expense	12.24	41.99	29.88	125.96
	Depreciation and Amortisation expense	0.26	0.37	0.24	1.08
	Other Expenses	18.43	25.97	65.12	198.49
	Total Expenses	31.17	71.36	102.49	348.02
V	Profit/(Loss) from before Exceptional Items and tax (I-IV)	(26.33)	(41.96)	(60.27)	(189.01)
VI	Exceptional Items				
VII	Profit/(Loss) before tax (V-VI)	(26.33)	(41.96)	(60.27)	(189.01)
VIII	Tax Expense:				
	Current Tax	-	-	-	-
	Deferred Tax	-	-	-	-
IX	Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(26.33)	(41.96)	(60.27)	(189.01)
X	Profit/ (Loss) from discontinuing operations				
XI	Tax Expense of discontinuing operations				
XII	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)				
XIII	Profit/ (Loss) for the period (IX+XII)	(26.33)	(41.96)	(60.27)	(189.01)
XIV	Other Comprehensive Income				
	A) (i) Items that will not be reclassified to profit or loss				
	(ii) Income Tax related to items that will not be reclassified to profit or loss				
	B) (i) Items that will be reclassified to profit or loss				
	(ii) Income Tax relating to items that will be reclassified to profit or loss		1.85	-	1.85
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(26.33)	(40.11)	(60.27)	(187.16)
XVI	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)				
	1) Basic	(0.18)	(0.18)	(0.27)	(1.28)
	2) Diluted	(0.18)	(0.18)	(0.43)	(1.28)
XVII	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)				
	1) Basic	-	-	-	-
	2) Diluted	-	-	-	-
XVIII	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)				
	1) Basic	(0.18)	(0.27)	(0.43)	(1.28)
	2) Diluted	(0.18)	(0.27)	(0.43)	(1.28)
XIX	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	1480.87	1480.87	1480.87	1480.87



Notes:

- 1 The above unaudited standalone financial results for the quarter ended 30 June 2020 have been subject to a limited review by the statutory auditors, and reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on Monday 14 September 2020.
- 2 The unaudited standalone financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under section 133 of Companies Act, 2013 and other accounting principles generally accepted in India and in terms Regulation 33 of SEBI (LODR) Regulations, 2015.
- 3 The format for the Standalone Unaudited quarterly results as prescribed in SEBI Circular CRI/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with the requirements of SEBI Circular CRI/CFD/FAC/62/2016 dated July 5, 2016 and exemption as given under clause 2.6.2(i) has been availed.
- 4 The World Health Organization announced a global health emergency because of a new strain of coronavirus ("COVID-19") and classified its outbreak as a pandemic on March 11, 2020. On March 24, 2020, the Indian government announced a strict 21-day lockdown across the country to contain the spread of the virus, which was further extended till June 4, 2020. This pandemic and government response are creating disruption in global supply chain and adversely impacting most of the industries which has resulted in global slowdown.
The company continues to consider the impact of COVID-19 pandemic in assessing the improvement of business and recoverability of receivables. For this purpose, the company considered internal and external sources of information up to the date of approval of these financial results.
The Company based on its judgements, estimates and assumptions expects to recover the carrying amount of receivables and other assets.
The impact of the global health pandemic may be different from that estimated as at the date of approval of financial results and the Company will continue to closely monitor any material changes to future economic conditions.
- 5 The EPS for quarters has not been annualised.
- 6 The Company has only one reportable segment i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.
- 7 The unaudited financial results for the quarter ended 30 June 2020 are also available on the website of the Company www.drhlsl.com
- 8 The Previous year's/quarter's figures have been regrouped/rearranged wherever necessary, for the purpose of comparison.

Place : Hyderabad
Date 14/9/2020

For DR HABEEBULLAH LIFE SCIENCES LIMITED



K. Krishnam Raju


Executive Chairman (DIN 00874858)



PART-I

CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER I ENDED 30TH JUNE, 2020

S.No	Particulars	Quarter ended			
		3 Months ended 30-06-2020	Preceding 3 months ended 31-03-2020	Corresponding 3 months ended in previous year 30-06-2019	Previous Year Ended 31- 03-2020
		Unaudited	Audited	Unaudited	Audited
I	Revenue from Operations	1.30	24.20	42.22	143.19
II	Other Income	3.54	5.20	-	15.82
III	Total Revenue (I+II)	4.84	29.40	42.22	159.01
IV	Expenses	-	-	-	-
	Cost of Material Consumed	0.19	3.03	7.25	22.49
	Employee benefits expense	12.84	45.34	30.83	139.96
	Depreciation and Amortisation expense	0.33	0.70	0.24	1.63
	Other Expenses	18.63	27.27	72.93	200.20
	Total Expenses	31.99	77.34	111.25	364.28
V	Profit/(Loss) from before Exceptional Items and tax (I-IV)	(27.15)	(47.94)	(69.03)	(205.27)
VI	Exceptional Items	-	-	-	-
VII	Profit/(Loss) before tax (V-VI)	(27.15)	(47.94)	(69.03)	(205.27)
VIII	Tax Expense:	-	-	-	-
	Current Tax	-	-	-	-
	Deferred Tax	-	(7.11)	-	(7.11)
IX	Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(27.15)	(40.83)	(69.03)	(198.16)
X	Profit/ (Loss) from discontinuing operations	-	-	-	-
XI	Tax Expense of discontinuing operations	-	-	-	-
XII	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)	-	-	-	-
XIII	Profit/ (Loss) for the period (IX+XII)	(27.15)	(40.83)	(69.03)	(198.16)
XIV	Other Comprehensive Income				
	A) (i) Items that will not be reclassified to profit or loss				
	(ii) Income Tax related to items that will not be reclassified to profit or loss				
	B) (i) Items that will be reclassified to profit or loss				
	(ii) Income Tax relating to items that will be reclassified to profit or loss		1.85	-	1.85
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(27.15)	(38.98)	(69.03)	(196.31)
XVI	Comprehensive Income attributable to Non Controlling Interest	-	-	-	(4.45)
XVII	Comprehensive Income attributable to Owners of the company	-	-	-	(191.86)
XVIII	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)				
	1) Basic	(0.19)	(0.26)	(0.42)	(1.31)
	2) Diluted	(0.19)	(0.26)	(0.42)	(1.31)
XIX	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)				
	1) Basic	-	-	-	-
	2) Diluted	-	-	-	-
XX	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)				
	1) Basic	(0.19)	(0.26)	(0.42)	(1.31)
	2) Diluted	(0.19)	(0.26)	(0.42)	(1.31)
XXI	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	1480.87	1480.87	1480.87	1480.87




Notes:

- 1 The above unaudited consolidated financial results for the quarter ended 30 June 2020 have been subject to a limited review by the statutory auditors, and reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on Monday 14 September 2020.
- 2 The unaudited consolidated financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under section 133 of Companies Act, 2013 and other accounting principles generally accepted in India and in terms Regulation 33 of SEBI (LODR) Regulations, 2015.
- 3 The format for the Standalone Unaudited quarterly results as prescribed in SEBI Circular CRI/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with the requirements of SEBI Circular CRI/CFD/FAC/62/2016 dated July 5, 2016 and exemption as given under clause 2.6.2(i) has been availed.
- 4 The World Health Organization announced a global health emergency because of a new strain of coronavirus ("COVID-19") and classified its outbreak as a pandemic on March 11, 2020. On March 24, 2020, the Indian government announced a strict 21-day lockdown across the country to contain the spread of the virus, which was further extended till June 4, 2020. This pandemic and government response are creating disruption in global supply chain and adversely impacting most of the industries which has resulted in global slowdown.
The company continues to consider the impact of COVID-19 pandemic in assessing the improvement of business and recoverability of receivables. For this purpose, the company considered internal and external sources of information up to the date of approval of these financial results.
The Company based on its judgements, estimates and assumptions expects to recover the carrying amount of receivables and other assets.
The impact of the global health pandemic may be different from that estimated as at the date of approval of financial results and the Company will continue to closely monitor any material changes to future economic conditions.
- 5 The EPS for quarters has not been annualised.
- 6 The Company has only one reportable segment i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.
- 7 The unaudited financial results for the quarter ended 30 June 2020 are also available on the website of the Company www.drhlsl.com
- 8 The Previous year's/quarter's figures have been regrouped/rearranged wherever necessary, for the purpose of comparison.


Place : Hyderabad
Date : 14/9/2020

For DR HABEEBULLAH LIFE SCIENCES LIMITED



K. Krishnam Raju

Executive Chairman (DIN 00074557)



Independent Auditor's Review Report on unaudited quarterly financial results of Dr Habeebullah Life Sciences Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended


To,
The Board of Directors
Dr Habeebullah Life Sciences Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Dr Habeebullah Life Sciences Limited** ('the Company') for the quarter ended June 30, 2020 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulation').
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted and procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone financial results prepared in accordance with the recognition and



measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For MSKA & Associates
Chartered Accountants
ICAI Firm Registration No.105047W



Ananthakrishnan Govindan
Partner
Membership No.: 205226
UDIN: 20205226AAAAGZ3476
Place: Hyderabad
Date: September 14, 2020



Independent Auditor's Review Report on Consolidated Unaudited Quarterly financial results of Dr Habeebullah Life Sciences Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors
Dr Habeebullah Life Sciences Limited

1. We have reviewed the accompanying statement of consolidated unaudited financial results of Dr Habeebullah Life Sciences Limited ('the Holding Company'), its subsidiary, (the Holding Company and its subsidiary together referred to as the 'Group') for the quarter ended June 30, 2020 ('the Statement'), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulations').
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



This Statement includes the results of the following entities:

Sr. No	Name of the Company	Relationship with the Holding Company
1	Krisani Bio Sciences Private Limited	Subsidiary

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors, nothing has come to our attention that causes us to believe that the accompanying Statement are prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The consolidated unaudited financial results include the interim financial information of subsidiary, (mentioned in paragraph 3 above) which have not been reviewed or audited by their auditors, whose interim financial information reflect total revenue (before consolidation adjustments) of Nil and total loss after tax (before consolidation adjustments) of Rs. 0.82 lakhs for the quarter ended June 30, 2020, respectively, as considered in the statement. According to the information and explanations given to us by the Management, this interim financial information is not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

For MSKA & Associates
Chartered Accountants
ICAI Firm Registration No.105047W



Ananthakrishnan Govindan
Partner
Membership No.: 205226
UDIN: 20205226AAAAHB8004
Place: Hyderabad
Date: September 14, 2020

